American College of Radiology and University of Pennsylvania Create Joint Program to Advance Quantitative Imaging Diagnostics and Analytics

October 14, 2020

The American College of Radiology ® Center for Research and Innovation™ (CRI) has announced a new collaborative effort with the Center for Biomedical Image Computing & Analytics (CBICA) in the Perelman School of Medicine at the University of Pennsylvania (Penn). The collaboration will leverage the ACR’s industry-leading research infrastructure and Penn’s scientific expertise in a joint effort to more rapidly advance imaging informatics.

Penn and the American College of Radiology CRI will focus on developing and hosting analytic tools that will be made available to the broader community through the ACR Data Analysis and Research Toolkit (DART) or other platforms, as appropriate. The first example is the Cancer Imaging Phenomics Toolkit (CaPTk), a software platform for the analysis of radiographic cancer images, currently focusing on the brain, breast, and lung cancer. CaPTk aims to facilitate the swift translation of advanced computational algorithms into routine clinical quantification, analysis, decision making, and reporting workflow. Its long-term goal is providing widely used technology that leverages the value of advanced imaging analytics in cancer prediction, diagnosis and prognosis, as well as in better understanding the biological mechanisms of cancer development. Follow-up directions include involvement in the Federated Tumor Segmentation initiative (FeTS), which aims at facilitating privacy-preserving multi-institutional collaborations on computational analyses without sharing patient data.

“Data and tool-hosting platforms like DART play an important role in data processing and the radiomic, pathomic and genomic analysis used to develop AI algorithms and advance virtual clinical trials,” says Etta D. Pisano, MD, FACR, chief research officer of the American College of Radiology. “The ACR is committed to making more tools available in DART that support researchers and data scientists who are working to build these automated capabilities.”

“Our goal in this collaboration is not only to make these computational tools more publicly available but ultimately to leverage such synergies and the DART to be able to evaluate radiomics biomarkers, such as the ones enabled by CaPTk, in prospective oncologic clinical trials,” said Despina Kontos, Ph.D., an associate professor of Radiology at Penn, co-chair of the ECOG-ACRIN Radiomics Working Group and a member of the computational science lab.

Sites interested in participating can learn more about the project by contacting Michael Boss, Ph.D., director of the ACR Imaging Core Laboratory at mboss@acr.org.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”